塞瑞替尼与克唑替尼治疗老年ALK融合基因阳性晚期非小细胞肺癌的疗效比较

doi:10.3969/j.issn.1671-7171.2022.03.020

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (1205 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要【目的】比较塞瑞替尼与克唑替尼治疗老年间变性淋巴瘤激酶(ALK)融合基因阳性晚期非小细胞肺癌(NSCLC)患者的疗效。【方法】选择本院收治的74例ALK融合基因阳性的晚期NSCLC患者作为研究对象,根据患者治疗方案将其分为A组和B组;其中A组44例给予塞瑞替尼治疗,B组30例给予克唑替尼治疗。比较两组患者治疗1个疗程后的临床疗效、生存质量(EORTC QLQ-C30评分)及不良反应发生率,比较两组患者随访1年内的生存情况。【结果】A组的疾病控制率为84.09%(37/44),高于B组的63.33%(19/30),且差异具有统计学意义(P<0.05);治疗后,两组患者EORTC QLQ-C30评分较治疗前均降低(P<0.05),且A组低于B组(P<0.05);两组患者的各项不良反应发生率比较差异无统计学意义(P>0.05);A组1年生存率为68.18%(30/44),高于B组的43.33%(13/30),且差异有统计学意义(P<0.05)。【结论】相比于克唑替尼, 给予ALK融合基因阳性的NSCLC患者塞瑞替尼治疗,可有效提升患者的疾病控制率,提高患者生活质量,延长患者生存周期且安全性良好。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	刘倩
	黄明华
	孙金林

关键词 ：癌,非小细胞肺/药物疗法, 抗肿瘤药/治疗应用, 老年人, 治疗结果

Abstract：【Objective】Comparison of the efficacy of ceritinib and crizotinib in the treatment of elderly patients of advanced non-small cell lung cancer (NSCLC) with positive anaplastic lymphoma kinase (ALK) fusion gene.【Methods】A total of 74 patients of advanced NSCLC with positive ALK fusion gene, who admitted to our hospital, were selected as the research objects. According to the treatment plan, patients were divided into A group with ceritinib treatment a(n=44) and B group with crizotinib treatment (n=30). The clinical efficacy, quality of life (EORTC QLQ-C30) and adverse reactions after one course of treatment were compared between the two groups of patients. Survival within 12 months in the two groups of patients was recorded. 【Results】The disease control rate of A group was 84.09%, which was higher than that of B group (63.33%), and the difference was statistically significant (P<0.05). After treatment, the EORTC QLQ-C30 scores of the two groups were both lower than before treatment, and the score of A group was lower than that of B group (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05), the 1-year survival rate of A group (68.18%) was higher than that of B group (43.33%), the difference was statistically significant (P<0.05). 【Conclusion】Compared to crizotinib, the treatment of ceritinib in NSCLC elderly patients with positive ALK fusion gene can more effectively improve the patient's disease control rate, improve the quality of life, extend the life cycle and have good safety.

Key words： Carcinoma, Non-Small-Cell Lung/DT Antineoplastic Agents /TU Aged Treatment Outcome

收稿日期: 2021-09-10

中图分类号:

R730.26

通讯作者: * E-mail:sunjinlin@163.com

引用本文:

刘倩, 黄明华, 孙金林. 塞瑞替尼与克唑替尼治疗老年ALK融合基因阳性晚期非小细胞肺癌的疗效比较[J]. 医学临床研究, 2022, 39(3): 393-396.
LIU Qian, HUANG Min-hua, SUN Jin-lin. Efficacy Comparison of Ceritinib and Crizotinib in the Treatment of Advanced Non-small Cell Lung Cancer with Positive ALK Fusion in Elderly Patients. JOURNAL OF CLINICAL RESEARCH, 2022, 39(3): 393-396.

链接本文:

http://journal07.magtech.org.cn/yxlcyj/CN/10.3969/j.issn.1671-7171.2022.03.020 或 http://journal07.magtech.org.cn/yxlcyj/CN/Y2022/V39/I3/393

[1] RECKAMP K,LIN H M,HUANG J,et al. Comparative efficacy of brigatinib versus ceritinib and alectinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small cell lung cancer[J].Curr Med Res Opin,2019,35(4):569-576.
[2] SORIA J C,TAN D,CHIARI R,et al. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised,open-label,phase 3 study[J].Lancet,2017,389(10):917-929.
[3] SHAW A T,KIM T M,CRINO L,et al. Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised,controlled,open-label,phase 3 trial[J].Lancet Oncol,2017,18(7):874-886.
[4] CLAXTON L,O'CONNOR J,WOOLACOTT N,et al. Ceritinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer: an evidence review group evaluation of a nice single technology appraisal[J].Pharmacoeconomics,2019,37(5):645-654.
[5] FELIP E,de BRAUD F G,MAUR M,et al. Ceritinib plus nivolumab in patients with advanced alk-rearranged non-small cell lung cancer: results of an open-label,multicenter,phase 1B study[J].J Thorac Oncol,2020,15(3):392-403.
[6] 支修益,石远凯,于金明. 中国原发性肺癌诊疗规范(2015年版)[J].中华肿瘤杂志,2015,37(1):67-78.
[7] EISENHAUER E A,THERASSE P,BOGAERTS J,et al.New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).[J].Eur J Cancer,2009,45(2):228-247.
[8] LAIRD B J,FALLON M,HJEMSTAD M J,et al. Quality of life in patients with advanced cancer: differential association with performance status and systemic inflammatory response[J].J Clin Oncol,2016,34(23):2769-2775.
[9] BOYD M R,PAULL K D. Some practical considerations and applications of the national cancer institute in vitro anticancer drug discovery screen[J].Drug Development Res,2010,34(2):91-109.
[10] BLAKELY C M,RIESS J W. Interpretation of ceritinib clinical trial results and future combination therapy strategies for ALK-rearranged NSCLC[J].Expert Rev Anticancer Ther,2019,19(12):1061-1075.
[11] RUSSO A,PARET C,ALT F,et al. Ceritinib-induced regression of an insulin-like growth factor-driven neuroepithelial brain tumor[J].Int J Mol Sci,2019,20(17):163-165.
[12] MOK T,CRINO L,FELIP E,et al. The accelerated path of ceritinib: Translating pre-clinical development into clinical efficacy[J].Cancer Treat Rev,2017,55(4):181-189.
[13] LIM S M,KIM H R,LEE J S,et al. Open-label,multicenter,phase Ⅱ study of ceritinib in patients with non-small-cell lung cancer harboring ROS1 rearrangement[J].J Clin Oncol,2017,35(23):2613-2618.
[14] DAVIES J,MARTINEC M,DELMAR P,et al. Comparative effectiveness from a single-arm trial and real-world data: alectinib versus ceritinib[J].J Comp Eff Res,2018,7(9):855-865.
[15] KIM D W,MEHRA R,TAN D,et al. Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre,open-label,phase 1 trial[J].Lancet Oncol,2016,17(4):452-463.